These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38052729)

  • 1. Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion.
    Frank A; Ismail Z; Wilson M; Gauthier S; Verret L; Hsiung GR; Borrie M
    Can J Neurol Sci; 2023 Dec; ():1-9. PubMed ID: 38052729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigating the future of Alzheimer's care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems.
    Leroi I; Dolphin H; Dinh R; Foley T; Kennelly S; Kinchin I; O'Caoimh R; O'Dowd S; O'Philbin L; O'Reilly S; Trepel D; Timmons S
    BMC Health Serv Res; 2024 Jun; 24(1):705. PubMed ID: 38840115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Model Predicting Healthcare Capacity Gaps For Alzheimer's Disease-Modifying Treatment in Canada.
    Black SE; Budd N; Nygaard HB; Verret L; Virdi S; Tamblyn Watts L; Wilson M
    Can J Neurol Sci; 2024 Jul; 51(4):487-494. PubMed ID: 37593895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements.
    Tahami Monfared AA; Phan NTN; Pearson I; Mauskopf J; Cho M; Zhang Q; Hampel H
    Neurol Ther; 2023 Aug; 12(4):1257-1284. PubMed ID: 37261607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management.
    Smith B; Ownby RL
    Cureus; 2024 Mar; 16(3):e56105. PubMed ID: 38618323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare.
    Wahlberg K; Winblad B; Cole A; Herring WL; Ramsberg J; Torontali I; Visser PJ; Wimo A; Wollaert L; Jönsson L
    J Intern Med; 2024 Mar; 295(3):281-291. PubMed ID: 38098165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.
    Dobson R; Patterson K; Malik R; Mandal U; Asif H; Humphreys R; Payne M; O-Charoenrat E; Huzzey L; Clare A; Green K; Morton M; Sohrabi C; Singh N; Pasupathy A; Patel M; Whiteman S; Maxmin K; Bass N; Gupta B; Cooper C; Marshall C; Weil RS; Mummery CJ
    J Neurol Neurosurg Psychiatry; 2024 Aug; 95(9):796-803. PubMed ID: 38862265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
    Ritchie CW; Russ TC; Banerjee S; Barber B; Boaden A; Fox NC; Holmes C; Isaacs JD; Leroi I; Lovestone S; Norton M; O'Brien J; Pearson J; Perry R; Pickett J; Waldman AD; Wong WL; Rossor MN; Burns A
    Alzheimers Res Ther; 2017 Oct; 9(1):85. PubMed ID: 29070066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer's Disease.
    Tahami Monfared AA; Tafazzoli A; Ye W; Chavan A; Deger KA; Zhang Q
    Neurol Ther; 2022 Dec; 11(4):1609-1623. PubMed ID: 35960495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for Alzheimer's disease: what's new on the horizon?
    Khoury R; Gallop A; Roberts K; Grysman N; Lu J; Grossberg GT
    Expert Opin Pharmacother; 2022 Aug; 23(11):1305-1323. PubMed ID: 35793398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based biomarkers in Alzheimer's disease: Future directions for implementation.
    Suridjan I; van der Flier WM; Monsch AU; Burnie N; Baldor R; Sabbagh M; Vilaseca J; Cai D; Carboni M; Lah JJ
    Alzheimers Dement (Amst); 2023; 15(4):e12508. PubMed ID: 38058357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease.
    Saposnik G; Sánchez-Benavidez G; García-Arcelay E; Franco-Macías E; Bensi C; Carmelingo S; Allegri RF; Pérez-Martínez DA; Maurino J
    Neurol Ther; 2023 Jun; 12(3):995-1006. PubMed ID: 36952172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in pre-clinical diagnosis of Alzheimer's disease.
    Zhou J; Benoit M; Sharoar MG
    Metab Brain Dis; 2022 Aug; 37(6):1703-1725. PubMed ID: 33900524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank.
    Vitek MP; Araujo JA; Fossel M; Greenberg BD; Howell GR; Rizzo SJS; Seyfried NT; Tenner AJ; Territo PR; Windisch M; Bain LJ; Ross A; Carrillo MC; Lamb BT; Edelmayer RM
    Alzheimers Dement (N Y); 2020; 6(1):e12114. PubMed ID: 33457489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With machine learning: the PREVIEW study protocol.
    Mazzeo S; Lassi M; Padiglioni S; Vergani AA; Moschini V; Scarpino M; Giacomucci G; Burali R; Morinelli C; Fabbiani C; Galdo G; Amato LG; Bagnoli S; Emiliani F; Ingannato A; Nacmias B; Sorbi S; Grippo A; Mazzoni A; Bessi V
    BMC Neurol; 2023 Aug; 23(1):300. PubMed ID: 37573339
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.